Abstract
Patients with cancer and viral hepatitis have usually been excluded from many clinical trials with ICIs. Therefore, the clinical impact of hepatitis C virus (HCV) infection in these patients has been poorly explored. DAA agents lead to a viral clearance of HCV in more than 90% of cases, and preclinical data correlated the decline of HCV-RNA at 14 days from the start of DAA therapy with the virological outcome (i.e. the sustained virological response [SVR], defined as undetectable HCV-RNA at 12 [SVR12] or 24 [SVR24] weeks from the end of the DAA therapy).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
